Hear from our CEO, Adrian Treverton, about treating non-melanoma skin cancer patients safely during COVID. Patients most likely to develop basal or squamous cell carcinoma are those in the age range at greater risk of serious illness from COVID, so safe and short treatment options are important.
Xstrahl to Highlight Superficial and Orthovoltage Radiotherapy Solutions for Skin Cancer and Selective Benign Conditions at AAPM 2024
Xstrahl, a global leader in the delivery of superficial radiation therapy devices and preclinical radiation research systems, will demonstrate Xstrahl 200, a modern orthovoltage radiotherapy solution for treating superficial lesions, skin cancers, and selective benign conditions at the 66th Annual Meeting & Exhibition of the American Association of Physicists in Medicine (AAPM) in Los Angeles, CA, from July 21-25, 2024, at booth 518.